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We evaluated treatment outcomes in a prospective registry of human immunodeﬁciency virus/hepatitis C virus (HCV)–coinfected
patients treated with interferon-free direct-acting antiviral agent–based therapy in hospitals from the region of Madrid between
November 2014 and August 2016. We assessed sustained viral response at 12 weeks after completion of treatment and used multi-
variable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% did not have cir-
rhosis, 33.9% had compensated cirrhosis, and 6.6% had decompensated cirrhosis. The predominant HCV genotypes were 1a
(40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens included sofosbuvir (SOF)/ledipasvir (61.9%), SOF plus
daclatasvir (14.6%), dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), and other regimens (10.3%). Ribavirin was used in
30.6% of patients. Less than 1% of patients discontinued therapy owing to adverse events. The frequency of sustained viral response
by intention-to-treat analysis was 92.0% (95% conﬁdence interval, 90.9%-93.1%) overall, 93.8% (92.4%-95.0%) for no cirrhosis,
91.0% (88.8%-92.9%) for compensated cirrhosis, and 80.8% (73.7%-86.6%) for decompensated cirrhosis. The factors associated
with treatment failure were male sex (adjusted odds ratio, 1.75; 95% conﬁdence interval, 1.14-2.69), Centers for Diseases Control
and Prevention category C (adjusted odds ratio, 1.65; 95% conﬁdence interval, 1.12-2.41), a baseline cluster of differentiation 4–
positive (CD41) T-cell count <200/mm3 (adjusted odds ratio, 2.30; 95% conﬁdence interval, 1.35-3.92), an HCV RNA load
800,000 IU/mL (adjusted odds ratio, 1.63; 95% conﬁdence interval, 1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35;
95% conﬁdence interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95% conﬁdence interval, 1.76-4.87), and
the use of SOF plus simeprevir, SOF plus ribavirin, and simeprevir plus daclatasvir. Conclusion: In this large real-world study,
direct-acting antiviral agent–based therapy was safe and highly effective in coinfected patients; predictors of failure included gender,
human immunodeﬁciency virus–related immunosuppression, HCV RNA load, severity of liver disease, and the use of suboptimal
direct-acting antiviral agent–based regimens. (HEPATOLOGY 2018;68:32-47).
The introduction of direct-acting antiviralagents (DAAs) represents a breakthrough inthe treatment of infection by hepatitis C virus
(HCV).(1) This therapeutic advance provided new
opportunities for the treatment of persons coinfected
by HCV and the human immunodeﬁciency virus
(HIV), one of the most difﬁcult-to-treat populations
in the interferon plus ribavirin (RBV) era, with sus-
tained viral response (SVR) rates in real-world settings
of slightly more than 30%.(2)
Abbreviations: ART, antiretroviral therapy; CD4, cluster of differentiation 4; CDC, Centers for Disease Control and Prevention; DAA, direct-act-
ing antiviral agent; DCV, daclatasvir; DSV, dasabuvir; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; ITT, intent-to-treat; LDV,
ledipasvir; Madrid-CoRe, Madrid Coinfection Registry; m-ITT, modiﬁed ITT; OBV/PTV/r, ombitasvir/paritaprevir/ritonavir; RBV, ribavirin;
SERMAS, Madrid Regional Health Service; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained viral response.
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Current guidelines recommend that HIV/HCV-
coinfected persons be treated using the approach fol-
lowed for non–HIV-infected individuals because the
efﬁcacy of currently licensed DAA regimens does not
appear to differ between HCV-monoinfected and coin-
fected individuals.(3,4) In the ﬁeld of anti-HCV therapy,
concern has been raised about the generalizability of
inclusion criteria from clinical trials of different DAAs
to the highly heterogeneous population of HIV/HCV-
coinfected patients.(5) Several studies have reported on
the real-world safety and effectiveness of DAAs in coin-
fected individuals. However, except for a report from
the Veterans Affairs Health Care System on 996
patients,(6) series are limited by small sample size or by
the inclusion of speciﬁc patient groups such as those
with cirrhosis or patients taking speciﬁc DAA regi-
mens.(7-10) This contrasts with real-world cohorts compris-
ing thousands of HCV-monoinfected individuals treated
with a wide spectrum of DAA-based regimens.(11)
We evaluated the response to treatment in a large
prospective registry of HIV/HCV-coinfected persons
receiving DAA-based HCV therapy in the region of
Madrid (Spain) and analyzed factors associated with
treatment failure.
Materials and Methods
DESIGN AND PATIENT
SELECTION
In the region of Madrid, as in other parts of Spain,
anti-HCV therapy is provided by hospital pharmacies
and is covered by the National Health System, to
which the Madrid Regional Health Service (SER-
MAS) belongs. In November 2014, SERMAS created
a compulsory prospective registry of individuals receiv-
ing DAAs for HCV infection in SERMAS hospitals.
Providing baseline data for this online registry is
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mandatory for the retrieval of DAAs in SERMAS
hospital pharmacies. Likewise, providing exhaustive
follow-up data is a condition for reimbursement.
The Madrid Coinfection Registry (Madrid-CoRe)
was created to determine the effectiveness and safety of
all-oral DAAs in HIV/HCV-coinfected patients in the
region of Madrid. The study protocol was approved by
the ethics committee of Hospital Universitario La Paz
for the analysis of anonymous routine clinical data with-
out written informed consent for purposes of scientiﬁc
publication.
In this analysis, patients included in the SERMAS
online registry were eligible if they were 18 years or
older, were infected with HIV, were receiving treat-
ment with all-oral DAAs for HCV infection, and were
scheduled to ﬁnish treatment on or before August 31,
2016. Retreatments were excluded from this analysis.
TREATMENT
During the study period, the criteria for access to
DAA therapy within SERMAS were conﬁrmed
HCV infection and presence of signiﬁcant ﬁbrosis
(METAVIR F2 or F3 in liver biopsy or liver stiffness
>7 kPa by transient elastography) or cirrhosis. In addi-
tion, DAA therapy could be administered irrespective
of ﬁbrosis stage to patients with signiﬁcant extrahe-
patic manifestations of HCV, such as symptomatic
cryoglobulinemia, and to patients at risk of transmit-
ting HCV, such as injection drug users, men who have
sex with men with high-risk sexual practices for sexu-
ally acquired HCV, and women of childbearing age
who wish to become pregnant. Available individual or
ﬁxed combinations of DAAs during the study period
included sofosbuvir (SOF), simeprevir (SMV), da-
clatasvir (DCV), ledipasvir (LDV)/SOF, ombitasvir/
paritaprevir/ritonavir (OBV/PTV/r), and dasabuvir
(DSV). The decision to treat and the selection of the
regimen, including duration and use or not of con-
comitant RBV, were taken by the treating physician
according to current guidelines.
MEASUREMENTS
Baseline and follow-up data were entered into the
SERMAS registry by health care personnel at each
institution.
Baseline data not related to HIV included demo-
graphics, HCV genotype and subtype, HCV RNA
load, prior history of anti-HCV therapy, liver ﬁbrosis
stage, and presence or absence of cirrhosis. In patients
with cirrhosis, additional data collected included the
method of diagnosis, history and type of decompensa-
tion, history of hepatocellular carcinoma, whether the
patient was on the liver transplantation list or had
undergone liver transplantation, Child-Pugh-Turcotte
score, and Model for End-Stage Liver Disease score.
The date of initiation and type of DAA regimen, use
of RBV, and planned treatment duration were also
recorded.
Baseline HIV-related data collected prospectively
since November 2014 included whether the patient
was HIV-infected and was receiving antiretroviral
therapy (ART). In September 2016, a case report form
was used to collect the following HIV-related variables
ofﬂine: HIV transmission category, Centers for Dis-
ease Control and Prevention (CDC) clinical category,
baseline and nadir cluster of differentiation 4–positive
(CD41) T-cell counts, and baseline HIV viral load. In
March 2017, the online registry was modiﬁed to in-
clude all of the variables related to HIV infection men-
tioned above. Since then, this information has been
registered prospectively.
Fibrosis stage and cirrhosis were determined by liver
biopsy or transient elastography (FibroScan; Echo-Sens,
Paris, France), in which liver stiffness was deﬁned as a
value>12.5 kPa. Cirrhosis was also deﬁned by clinical evi-
dence of liver decompensation. For descriptive purposes
and analysis, patients with hepatocellular carcinoma were
considered to have decompensated cirrhosis. The remain-
ing liver stiffness cutoffs were as follows: 7 kPa, the cut-
off to rule out null or mild ﬁbrosis;<9.5 kPa, the cutoff to
rule out advanced ﬁbrosis-cirrhosis; and 19.5 kPa, the
cutoff to rule out high risk of esophageal varices among
patients with cirrhosis.(12)
HCV RNA measurements were performed at baseline,
weeks 12 and 24 of therapy (if applicable), and 12 weeks
after completion of treatment. Real-time PCR assays for
the quantiﬁcation of HCV RNA included Roche
COBAS AmpliPrep/COBAS TaqMan HCV (Roche
Molecular Systems, Pleasanton, CA; lower limit of detec-
tion, 15 IU/mL), Abbott RealTime HCV assay (Abbott
Laboratories, Abbott Park, IL; lower limit of detection, 12
IU/mL), or Siemens Versant HCV RNA version 1.0 (Sie-
mens Healthcare GmbH, Erlangen, Germany; lower limit
of detection, 15 IU/mL).
OUTCOMES
Follow-up data in the online registry included the
following: (1) SVR, deﬁned as an undetectable plasma
HCV RNA at 12 weeks after completion of treatment;
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(2) relapse, deﬁned as detectable posttreatment HCV
RNA after undetectable HCV RNA at the end of
therapy; and (3) viral breakthrough, deﬁned as detect-
able HCV RNA at the end of treatment and follow-up
week 12. Discontinuations due to adverse events or for
reasons other than adverse events, losses to follow-up,
and deaths were also registered.
STATISTICAL ANALYSIS
Efﬁcacy results were analyzed using the intent-to-treat
(ITT) approach and a modiﬁed ITT (m-ITT) approach,
in which nonvirological failures for reasons other than dis-
continuation of treatment secondary to adverse events or
death were not considered in the analysis. Multivariable
logistic regression models were used to identify indepen-
dent baseline factors associated with treatment failure by
ITT analysis (the primary analysis) and by m-ITT analysis.
Analyses were performed for the entire data set and for
subgroups of liver disease severity (absence of cirrhosis,
compensated cirrhosis, and decompensated cirrhosis).
Baseline factors were included in multivariable models if P
 0.1. Wald tests were used to derive P values. The analy-
ses were performed using Stata version 14 (StataCorp,
College Station, TX).
Results
PATIENT CHARACTERISTICS
During the study period, 2,435 HIV/HCV-coin-
fected patients initiating all-oral DAAs for HCV in 25
hospitals from the region of Madrid were eligible for
this study (Fig. 1). After exclusion of 39 patients for
whom information about treatment completion was
unavailable and 27 with pending SVR results after
completion of therapy, the ﬁnal study population com-
prised 2,369 patients. A total of 482 patients from
Madrid-CoRe were previously included in a study ana-
lyzing differences in treatment outcomes of DAA ther-
apy between HCV-monoinfected and HIV/HCV-
coinfected patients.(13) Also, fewer than 100 patients
from Madrid-CoRe were included in another study
assessing the frequency and predictors of treatment
failure to all-oral DAA therapy in patients who com-
pleted a course of all-oral DAA therapy before Decem-
ber 2015 in three Spanish hospitals, two of which
contributed to Madrid-CoRe.(14)
According to the severity of liver disease, there were
1,410 patients without cirrhosis (59.5%), 803 patients
with compensated cirrhosis (33.9%), and 156 patients
with decompensated cirrhosis (6.6%). The baseline
characteristics are shown in Table 1. In brief, 78.2%
were men, the median age was 51 years, and 63.9%
were naive for anti-HCV therapy. The predominant
HCV genotypes were 1a (40.9%), 4 (22.4%), 1b
(15.1%), and 3 (15.0%). The median HCV RNA was
6.3 log IU/mL. At baseline, 98.0% patients were on
ART. Full data on HIV-related characteristics (col-
lected ofﬂine) were available for analysis from only two
thirds of the patients in Madrid-CoRe as data from
patients from eight of the 25 hospitals were not avail-
able at the time of analysis (Table 1). In comparison
to patients with complete HIV data, those with
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FIG. 1. Flowchart.
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TABLE 1. Baseline Characteristics of Study Population
No
Cirrhosis
Compensated
Cirrhosis
Decompensated
Cirrhosis Total
Variables n 5 1,410 (59.5) n 5 803 (33.9) n 5 156 (6.6) N 5 2,369
Age, median (IQR) 50 (47-53) 51 (48-54) 51 (48-54) 51 (47-54)
Male sex, n (%) 1,085 (76.9) 656 (81.7) 111 (71.1) 1,852 (78.2)
Prior anti-HCV therapy, n (%)
No 953 (67.6) 464 (57.8) 96 (61.5) 1,513 (63.9)
Yes 457 (32.4) 338 (42.1) 60 (38.5) 855 (36.1)
Unknown 0 1 (0.1) 0 1 (0.04)
Genotype, n (%)
1
1a 596 (42.3) 318 (39.6) 54 (34.6) 968 (40.9)
1b 196 (13.9) 130 (16.2) 32 (20.5) 358 (15.1)
1 nonsubtyped 58 (4.1) 38 (4.7) 7 (4.5) 103 (4.3)
2 18 (1.3) 6 (0.7) 3 (1.9) 27 (1.1)
3 179 (12.7) 152 (18.9) 24 (15.4) 355 (15.0)
4 349 (24.7) 149 (18.6) 32 (20.5) 530 (22.4)
Mixed 12 (0.8) 9 (1.1) 3 (1.9) 24 (1.0)
Indeterminate 2 (0.1) 1 (0.1) 1 (0.6) 4 (0.2)
HCV RNA, n (%)
Unknown 0 0 0 0
Known 1,410 (100) 803 (100) 156 (100) 2,369 (100)
Log IU/mL, median (IQR) 6.3 (5.8-6.7) 6.2 (5.8-6.6) 6.0 (5.5-6.4) 6.3 (5.8-6.7)
Transient elastography, n (%)
No 12 (0.8) 12 (1.5) 14 (9.0) 38 (1.6)
Yes 1,398 (99.2) 791 (98.5) 142 (91.0) 2,331 (98.4)
Stiffness, kPa-Median (IQR) 8.2 (7.3-9.9) 21.3 (15.3-32.8) 31.8 (20.3-48.0) 10.4 (7.9-18.0)
HIV risk factor, n (%)
Injection drug use 744 (52.8) 529 (65.9) 97 (62.2) 1,370 (57.8)
Men who have sex with men 82 (5.8) 21 (2.6) 5 (3.2) 108 (4.6)
Heterosexual relations 68 (4.8) 27 (3.4) 7 (4.5) 102 (4.3)
Transfusions 10 (0.7) 5 (0.6) 1 (0.6) 16 (0.7)
Mother to child 2 (0.1) 1 (0.1) 0 3 (0.1)
Other/unknown 504 (35.7) 220 (27.4) 46 (29.5) 770 (32.5)
CDC clinical category, n (%)
A 356 (25.2) 222 (27.6) 39 (25.0) 617 (26.0)
B 235 (16.7) 133 (16.6) 36 (23.1) 404 (17.1)
C 319 (22.6) 226 (28.1) 38 (24.4) 583 (24.6)
Unknown 500 (35.5) 222 (27.6) 43 (27.6) 765 (32.3)
Nadir CD41/mm3, n (%)
>500 84 (6.0) 40 (5.0) 4 (2.6) 128 (5.4)
200-499 347 (24.6) 183 (22.8) 27 (17.3) 557 (23.5)
<200 477 (33.8) 358 (44.6) 82 (52.6) 917 (38.7)
Unknown 502 (35.6) 222 (27.6) 43 (27.6) 767 (32.4)
Baseline CD41/mm3, n (%)
Unknown 535 (37.9) 248 (30.9) 48 (30.8) 831 (35.1)
Known 875 (62.1) 555 (69.1) 108 (69.2) 1,538 (64.9)
Median (IQR) 628 (429-820) 523 (324-777) 374 (233-591) 575 (369-814)
HIV RNA, n (%)
Unknown 483 (34.3) 208 (25.9) 43 (27.6) 734 (31.0)
Known 927 (65.7) 595 (74.1) 113 (72.4) 1,635 (69.0)
Detectable 44 (4.7) 36 (6.0) 3 (2.6) 83 (5.1)
Undetectable 883 (95.3) 559 (94.0) 110 (97.4) 1,552 (94.9)
ART, n (%)
No 23 (1.6) 17 (2.1) 7 (4.5) 47 (2.0)
Yes 1,387 (98.4) 786 (97.9) 149 (95.5) 2,322 (98.0)
ART regimen before DAA Rx, n (%)
2nRTI11PI 77 (30.3) 58 (32.2) 21 (50.0) 156 (32.8)
2nRTI11 INSTI 13 (5.1) 19 (10.6) 2 (4.8) 34 (7.1)
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incomplete HIV data were on average 1 year older and
had a lower frequency of both compensated and
decompensated cirrhosis (Supporting Table S1). Infor-
mation about modiﬁcation of ART prior to the initia-
tion of DAA therapy was available for 1,613 patients,
476 of whom (29.5%) had their ART regimen modi-
ﬁed to prevent potentially clinically signiﬁcant drug
interactions between antiretroviral drugs and DAAs.
TREATMENT REGIMENS
Table 2 shows the all-oral DAA regimens used and
the duration of the treatment in weeks. In brief, SOF/
LDV was the most frequently used regimen in app-
roximately two thirds of the patients, followed by
SOF1DCV, DSV1OBV/PTV/r, and OBV/PTV/r.
Less commonly used regimens were SOF1SMV,
SOF1RBV, SMV1DCV, SOF1SMV1DCV, and
SOF1OBV/PTV/r. The distribution of all-oral DAA
regimens categorized by severity of liver disease is
shown in Table 3. The distribution of all-oral DAA
regimens categorized by genotype is shown in Support-
ing Table S2.
TREATMENT RESPONSE
Treatment Response According
to Liver Disease Severity
Treatment response according to liver disease cate-
gories by ITT and by m-ITT analyses is shown in Fig.
2. The frequency of SVR by ITT and by m-ITT anal-
ysis was 92.0% and 94.1%, respectively. The respective
values were 93.8% and 95.9% for patients without cir-
rhosis, 91.0% and 93.1% for patients with compen-
sated cirrhosis, and 80.8% and 82.4% for patients with
decompensated cirrhosis.
Treatment Response According
to DAA Regimen, Genotype,
and Liver Disease Severity
The response (by ITT and m-ITT analyses) to the
DAA regimens categorized by genotype and the sever-
ity of liver disease is shown in Table 4 and the
Supporting Information.
TABLE 1. Continued
No
Cirrhosis
Compensated
Cirrhosis
Decompensated
Cirrhosis Total
Variables n 5 1,410 (59.5) n 5 803 (33.9) n 5 156 (6.6) N 5 2,369
2nRTI11nnRTI 115 (45.3) 74 (41.1) 12 (28.6) 201 (42.2)
PI-based dual therapy 10 (3.9) 2 (1.1) 2 (4.8) 14 (2.9)
PI monotherapy 9 (3.5) 7 (3.9) 0 16 (3.4)
Other 29 (11.4) 18 (10.0) 5 (11.9) 52 (10.9)
Unknown 1 (0.4) 2 (1.1) 0 3 (0.6)
ART change prior to DAA Rx, n (%)
No 658 (47.4) 409 (52.0) 70 (47.0) 1,137 (49.0)
Yes 254 (18.3) 180 (22.9) 42 (28.2) 476 (20.5)
Unknown 475 (34.2) 197 (25.1) 37 (24.8) 709 (30.5)
Abbreviations: INSTI, integrase strand transfer inhibitor; IQR, interquartile range; nnRTI, non-nucleoside reverse transcriptase inhibi-
tor; nRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Rx, therapy.
TABLE 2. Treatment Regimens (Total N 5 2,369)
Regimen, no. (%)*
SOF/LDV
1,467 (61.9)
SOF1DCV
346 (14.6)
DSV1OBV/PTV/r
314 (13.2)
OBV/PTV/r
132 (5.6)
SOF1SMV
71 (3.0)
SOF1RBV
32 (1.3)
8 weeks 129 — 1 — —
12 weeks 832 140 105 6 27 —
12 weeks 1 RBV 104 58 151 114 18 13
16 weeks 1 3 — — — —
16 weeks 1 RBV — 3 — — — 1
24 weeks 303 69 3 — 21 —
24 weeks 1 RBV 98 73 54 12 5 18
*Other regimens not shown in the table: SMV1DCV, n 5 4; SOF1SMV1DCV, n 5 2; SOF1OBV/PTV/r, n 5 1.
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GENOTYPE 1A
For genotype 1a, the SVR rates of SOF/LDV by
ITT and m-ITT analyses were 92.5% and 94.8%,
respectively, for patients without cirrhosis, 94.5% and
97.6% for patients with compensated cirrhosis, and
79.3% and 85.2% for patients with decompensated cir-
rhosis. The SVR rates of DSV1OBV/PTV/r by ITT
and m-ITT analyses were both 95.8% for patients
without cirrhosis and 94.2% and 96.1%, respectively,
for patients with compensated cirrhosis.
GENOTYPE 1B
For genotype 1b, the SVR rates of SOF/LDV by
ITT and m-ITT analyses were 97.0% and 98.0%, res-
pectively, for patients without cirrhosis, 94.0% and
95.2% for patients with compensated cirrhosis, and
93.7% by both analyses for patients with decompensated
cirrhosis. The SVR rates of DSV1OBV/PTV/r by
ITT and m-ITT analyses were 96.8% and 97.8%,
respectively, for patients without cirrhosis and 87.1% by
both analyses for patients with compensated cirrhosis.
GENOTYPE 3
In patients without cirrhosis who had HCV genotype
3, the SVR rates of SOF1DCV by ITT and m-ITT
analyses were 95.3% and 98.2%, respectively. A total of
119 patients without cirrhosis received SOF1DCV
without RBV for 12 weeks, with SVR rates by ITT and
m-ITT analyses of 95.0% and 97.4%, respectively
(Supporting Table S3). In patients with HCV genotype
3 with compensated cirrhosis, the SVR rates of SOF1
DCV by ITT and m-ITT analyses were 91.6% and
95.0%, respectively. A total of 48 patients with compen-
sated cirrhosis received SOF1DCV plus RBV for 24
weeks, with SVR rates by ITT and m-ITT analyses of
93.7% and 97.8%, respectively (Supporting Table S3). In
patients with HCV genotype 3 with decompensated cir-
rhosis, the SVR rates of SOF1DCV by ITT and m-
ITT analyses were both 72.7%, although only 11 patients
were included in this last category. For genotype 3, the
SVR rates of SOF/LDV by ITT and m-ITT analyses
were 100% in patients without cirrhosis, although only
8 patients were included. For patients with compensated
cirrhosis, the SVR rates for this regimen were 90.8% and
92.2%, respectively. A total of 52 patients with compen-
sated cirrhosis received SOF/LDV plus RBV for 24
weeks, with SVR rates by ITT and m-ITT analyses of
88.5% and 90.2%, respectively (Supporting Table S4). In
patients with HCV genotype 3 and decompensated cir-
rhosis, the SVR rates of SOF/LDV by ITT and m-ITT
analyses were both 80.0%, although only 10 patients
were included in this last category.
GENOTYPE 4
For genotype 4, the SVR rates of SOF/LDV by
ITT and m-ITT analyses were 92.2% and 95.5%,
respectively, for patients without cirrhosis and 92.2%
and 93.9% for patients with compensated cirrhosis.
Among patients without cirrhosis, 218 received SOF/
LDV for 12 weeks and 111 received OBV/PTV/r for
12 weeks, with SVR rates by ITT and m-ITT analyses
of 91.7%-95.2% and 91.9%-94.4%, respectively (Sup-
porting Table S5). A total of 74 patients with compen-
sated cirrhosis received SOF/LDV without RBV for
24 weeks, with SVR rates by ITT and m-ITT analyses
of 93.2% and 94.5%, respectively (Supporting Table
S6). In patients with HCV genotype 4 and decompen-
sated cirrhosis, the SVR rates of SOF/LDV by ITT
and m-ITT analyses were both 80.0%, although only
20 patients were included in this last category. For this
same genotype, the SVR rates of OBV/PTV/r by ITT
and m-ITT analyses were 92.2% and 94.7%, respec-
tively, for patients without cirrhosis. The ﬁgures were
91.7% and 100%, respectively, for patients with com-
pensated cirrhosis, although only 11 patients were
included in this category.
TABLE 3. Treatment Regimens According to Severity of Liver Disease
Regimen, n (%)
No Cirrhosis
(n 5 1,410)
Compensated Cirrhosis
(n 5 803)
Decompensated Cirrhosis
(n 5 156)
Total
(N 5 2,369)
SOF/LDV 864 (61.3) 523 (65.1) 80 (51.3) 1,467 (61.9)
SOF1DCV 177 (12.5) 132 (16.4) 37 (23.7) 346 (14.6)
DSV1OBV/PTV/r 223 (15.8) 87 (10.8) 4 (2.6) 314 (13.2)
OBV/PTV/r 120 (8.5) 12 (1.5) — 132 (5.6)
SOF1SMV 9 (0.6) 36 (4.5) 26 (16.7) 71 (3.0)
SOF1RBV 16 (1.1) 8 (1.0) 8 (5.1) 32 (1.3)
SMV1DCV 1 (0.1) 2 (0.2) 1 (0.6) 4 (0.2)
SOF1SMV1DCV — 2 (0.2) — 2 (0.1)
SOF1OBV/PTV/r — 1 (0.1) — 1 (0.04)
Use of RBV 328 (23.3) 323 (40.2) 73 (46.8) 724 (30.6)
BERENGUER ET AL. HEPATOLOGY, July 2018
38
LDV/SOF for 8 Weeks
A total of 129 patients, 128 without cirrhosis and 1
with compensated cirrhosis, received SOF/LDV with-
out RBV for 8 weeks. The HCV genotype was 1 in
127 (98.4%) patients and 4 in 2 (1.6%) patients.
Eleven (8.5%) patients had previously been exposed
to pegylated interferon plus RBV. The median (inter-
quartile range) liver stiffness was 7.6 kPa (7.0-8.6
kPa), and the median (interquartile range) HCV RNA
was 1,100,000 IU/mL (333,907-3,140,000 IU/mL).
The overall SVR (95% conﬁdence interval) rate of
LDV/SOF for 8 weeks was 93.0% (87.2%-96.8%) by
ITT analysis and 93.8% (88.1%-97.3%) by m-ITT
analysis. In Madrid-CoRe, a total of 308 anti-HCV
treatment-naive patients without cirrhosis with HCV
genotype 1 and with an HCV-RNA <6 million (6.8
Log) IU/mL were treated with LDV/SOF without
RBV. Of these, 104 (33.8%) were treated for 8 weeks
and 204 for 12 weeks. The SVR by ITT and m-ITT
analyses for patients treated for 8 and 12 weeks were
92.3%-93.2% and 93.1%-95.0%, respectively. The
relapse rates for patients treated for 8 and 12 weeks
were 5.8% and 3.9%, respectively (P5 0.46) (Fig. 3).
VARIABLES ASSOCIATED WITH
TREATMENT FAILURE
Table 5 shows the results of univariable and multi-
variable logistic regression models to identify baseline
variables associated with treatment failure by ITT anal-
ysis for the full data set. In brief, factors independently
associated with an increased odds of treatment failure
by ITT analysis were male sex, CDC clinical category
C, a baseline CD41 T-cell count <200/mm3, an
HCV RNA load 800,000 IU/mL, liver cirrhosis,
decompensated liver disease, and the use of speciﬁc
DAA regimens (SOF1SMV, SOF1RBV, and
SMV1DCV). Similar ﬁndings were observed by m-
ITT analysis (Supporting Table S7).
We also performed separate logistic regression mod-
els to identify baseline variables associated with treat-
ment failure for the different categories of liver disease
severity. The results are shown in Supporting Informa-
tion. In brief, ITT analysis showed that the only varia-
bles independently associated with treatment in
patients without cirrhosis were male sex, CDC clinical
category C, and a baseline CD41 T-cell count <200/
mm3 (Supporting Tables S8 and S9). In patients with
compensated cirrhosis, the factors independently asso-
ciated with treatment failure by ITT analysis were
increasing age, liver stiffness 19.5 kPa, and the use
of SOF1SMV as anti-HCV regimens (Supporting
Tables S10 and S11). Finally, in patients with decom-
pensated cirrhosis, the factors independently associated
with treatment failure by ITT analysis were Child-
Pugh-Turcotte category C and a history of hepatocel-
lular carcinoma (Supporting Tables S12 and S13).
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FIG. 2. Treatment outcomes by severity of liver disease by ITT
(A) and by m-ITT analyses (B). Abbreviations: AE, adverse
events; CI, conﬁdence interval; Co-C, compensated cirrhosis;
DC, treatment discontinuations (number [%]); De-C, decompen-
sated cirrhosis; No-C, no cirrhosis.
                                                                 
HEPATOLOGY, Vol. 68, No. 1, 2018 BERENGUER ET AL.
39
TABLE 4. Treatment Response Categorized by Genotype, Severity of Liver Disease, and Treatment Regimen in Madrid-
CoRe
Genotype
1a 1b 3 4 Other All
Regimen—treated (% SVR-12)—patients without cirrhosis (ITT analysis)
n 5 596 n 5 196 n 5 179 n 5 349 n 5 90 N 5 1,410
SOF/LDV 470 (92.5) 101 (97.0) 8 (100) 230 (92.2) 55 (96.4) 864 (93.3)
SOF1DCV — — 170 (95.3) 1 (100) 6 (100) 177 (95.5)
DSV1OBV/PTV/r 118 (95.8) 93 (96.8) — 1 (100) 11 (90.9) 223 (96.0)
OBV/PTV/r 2 (100) 1 (100) — 116 (92.2) 1 (100) 120 (92.5)
SOF1SMV 5 (100) 1 (100) — 1 (100) 2 (100) 9 (100)
SOF1RBV — — 1 (100) — 15 (86.7) 16 (87.5)
SMV1DCV 1 (0) — — — — 1 (0)
Regimen—treated (% SVR-12)—patients without cirrhosis (m-ITT analysis)
n 5 585 n 5 194 n 5 174 n 5 338 n 5 89 N 5 1,380
SOF/LDV 459 (94.8) 100 (98.0) 8 (100) 222 (95.5) 54 (98.1) 843 (95.6)
SOF1DCV — — 165 (98.2) 1 (100) 6 (100) 172 (98.3)
DSV1OBV/PTV/r 118 (95.8) 92 (97.8) — 1 (100) 11 (90.9) 222 (96.4)
OBV/PTV/r 2 (100) 1 (100) — 113 (94.7) 1 (100) 117 (94.9)
SOF1SMV 5 (100) 1 (100) — 1 (100) 2 (100) 9 (100)
SOF1RBV — — 1 (100) — 15 (86.7) 16 (87.5)
SMV1DCV 1 (0) — — — — 1 (0)
Regimen—treated (% SVR-12)—patients with compensated cirrhosis (ITT analysis)
n 5 318 n 5 130 n 5 152 n 5 149 n 5 54 N 5 803
SOF/LDV 220 (94.5) 84 (94.0) 65 (90.8) 116 (92.2) 38 (89.5) 523 (93.1)
SOF1DCV 29 (86.2) 6 (83.3) 83 (91.6) 10 (70.0) 4 (75.0) 132 (87.9)
DSV1OBV/PTV/r 52 (94.2) 31 (87.1) — — 4 (100) 87 (91.9)
OBV/PTV/r — — — 12 (91.7) — 12 (91.7)
SOF1SMV 15 (73.3) 8 (87.5) — 9 (44.4) 4 (100) 36 (72.2)
SOF1RBV — — 4 (50.0) — 4 (100) 8 (75.0)
SMV1DCV — 1 (100) — 1 (100) — 2 (100)
SOF1SMV1DCV 2 (100) — — — — 2 (100)
SOF1OBV/PTV/r — — — 1 (100) — 1 (100)
Regimen—treated (% SVR-12)—patients with compensated cirrhosis (m-ITT analysis)
n 5 310 n 5 129 n 5 148 n 5 146 n 5 52 N 5 785
SOF/LDV 213 (97.6) 83 (95.2) 64 (92.2) 114 (93.9) 36 (94.4) 510 (95.5)
SOF1DCV 29 (86.2) 6 (83.3) 80 (95.0) 10 (70.0) 4 (75.0) 129 (89.9)
DSV1OBV/PTV/r 51 (96.1) 31 (87.1) — — 4 (100) 86 (93.0)
OBV/PTV/r — — — 11 (100) — 11 (100)
SOF1SMV 15 (73.3) 8 (87.5) — 9 (44.4) 4 (100) 36 (72.2)
SOF1RBV — — 4 (50.0) — 4 (100) 8 (75.0)
SMV1DCV — 1 (100) — 1 (100) — 2 (100)
SOF1SMV1DCV 2 (100) — — — — 2 (100)
SOF1OBV/PTV/r — — — 1 (100) — 1 (100)
Regimen—treated (% SVR-12)—patients with decompensated cirrhosis (ITT analysis)
n 5 54 n 5 32 n 5 24 n 5 32 n 5 14 N 5 156
SOF/LDV 29 (79.3) 16 (93.7) 10 (80.0) 20 (80.0) 5 (100) 80 (83.7)
SOF1DCV 9 (100) 6 (66.7) 11 (72.7) 7 (100) 4 (75.0) 37 (83.8)
DSV1OBV/PTV/r 4 (100) — — — — 4 (100)
SOF1SMV 10 (60.0) 9 (88.9) — 5 (60.0) 2 (100) 26 (73.1)
SOF1RBV 1 (100) 1 (100) 3 (66.7) — 3 (33.3) 8 (62.5)
SMV1DCV 1 (0) — — — — 1 (0)
Regimen—treated (% SVR-12)—patients with decompensated cirrhosis (m-ITT analysis)
n 5 52 n 5 32 n 5 23 n 5 32 n 5 14 N 5 153
SOF/LDV 27 (85.2) 16 (93.7) 10 (80.0) 20 (80.0) 5 (100) 78 (85.9)
SOF1DCV 9 (100) 6 (66.7) 11 (72.7) 7 (100) 4 (75.0) 37 (83.8)
DSV1OBV/PTV/r 4 (100) — — — — 4 (100)
SOF1SMV 10 (60.0) 9 (88.9) — 5 (60.0) 2 (100) 26 (73.1)
SOF1RBV 1 (100) 1 (100) 2 (100) — 3 (33.3) 7 (71.4)
SMV1DCV 1 (0) — — — — 1 (0)
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Discussion
We prospectively assessed the effectiveness and
safety of all-oral DAA therapy in approximately 2,400
HIV/HCV-coinfected patients, of whom 40% had
liver cirrhosis. The frequency of SVR by ITT and m-
ITT analyses was 92% and 94%, respectively. Less
than 1% of patients discontinued therapy because of
adverse events. In the ITT analysis, the factors inde-
pendently associated with an increased odds of treat-
ment failure were male sex, CDC clinical category C,
baseline CD41 T-cell count <200/mm3, HCV RNA
load 800,000 IU/mL, cirrhosis, decompensated liver
disease, and the use of speciﬁc DAA regimens (SOF1
SMV, SOF1RBV, and SMV1DCV).
Slightly more than 1,400 patients in Madrid-CoRe
were infected with HCV genotype 1a or 1b, which
were the predominant infecting genotypes. The rates
of SVR were high with LDV/SOF and DSV1OBV/
PTV/r in patients with compensated liver disease and
did not differ from the rates reported for this genotype
in clinical trials in HCV-monoinfected and HIV/
HCV-coinfected individuals for LDV/SOF(15-17) and
DSV1OBV/PTV/r.(18-20) Our ﬁndings also agree
with the real-world results of the Veterans Affairs
Health Care System, in which no differences in SVR
rates were found between DSV1OBV/PTV/r and
LDV/SOF regimens in a group of more than 5,000
patients with HCV genotype 1, the clear majority of
whom were HCV-monoinfected.(21)
Genotype 4 was the second most frequent infecting
genotype in Madrid-CoRe. Among patients without
cirrhosis who had this genotype, SOF/LDV and
OBV/PTV/r yielded very high SVR rates that were
similar to those reported in clinical trials for patients
without cirrhosis who had HCV genotype 4 and were
treated with the same regimens.(22-24) In Madrid-
CoRe, 116 genotype 4–infected patients with cirrhosis
were treated with SOF/LDV and 11 with OBV/
PTV/r. The SVR rates for SOF/LDV were the same
as those recorded in patients without cirrhosis and
were 100% for OBV/PTV/r.
In patients without cirrhosis who had genotype 3,
the SVR rates of SOF1DCV without RBV for 12
weeks were the same as those found with this same
regimen in genotype 3–infected patients without cir-
rhosis in the ALLY-3 clinical trial.(25) A total of 83
patients with genotype 3 and compensated cirrhosis
were treated with SOF1DCV with or without RBV
for different durations. Of these, 48 patients were
treated with SOF1DCV with RBV for 24 weeks,
with SVR rates of 94% and 98% by ITT and m-ITT
analyses. The SVR rates were below 90% for SOF1
DCV with RBV for 12 weeks or SOF1DCV without
RBV for 24 weeks, although the numbers of patients
treated with these two regimens were small. In the
ALLY-3 trial, a 12-week regimen of SOF1DCV
without RBV in 32 patients with cirrhosis yielded an
SVR rate of 63%.(25) In the ALLY-31 trial, a regimen
of SOF1DCV with RBV for 12 or 16 weeks in
patients with cirrhosis (18 patients in each arm)
yielded SVR rates of 83% and 89%, respectively.(26)
The results of Madrid-CoRe support the current rec-
ommendations of the European Association for the
Study of the Liver to use SOF1DCV with RBV for
24 weeks for genotype 3 infection in patients with
compensated cirrhosis, even though no clinical trials
support this recommendation.(3)
In Madrid-CoRe, one quarter of genotype 3–
infected patients, most of whom had cirrhosis, were
treated with SOF/LDV, a regimen that was prioritized
for this genotype during the ﬁrst months of the study
period owing to the lower costs of LDV/SOF com-
pared with SOF1DCV in the SERMAS system. A
total of 52 patients with compensated cirrhosis were
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FIG. 3. Treatment outcomes for SOF/LDV without RBV for
HCV genotype 1 (1a, 1b, or nonsubtyped 1) in treatment-naive,
patients without cirrhosis who had an HCV RNA <6 million
(6.8 log) IU/mL. Abbreviations: AE, adverse events; CI, conﬁ-
dence interval; DC, treatment discontinuations (number [%]);
No., number of patients.
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TABLE 5. Results From Univariable and Multivariable Logistic Regression Models to Identify Independent Baseline Factors
Predictive of Treatment Failure by ITT Analysis Considering All Categories of Liver-Disease Severity (N 5 2,369)
Treatment
Failures (n 5 189) Univariable Multivariable
Variable n (%) OR (95% CI) P OR (95% CI) P
Age (years) 0.03 0.089
<45 16 (5.6) 1.00 1.00
45-54 123 (7.3) 1.40 (0.82-2.40) 1.27 (0.73-2.19)
55 50 (10.7) 2.03 (1.13-3.64) 1.77 (0.98-3.22)
Sex 0.01 0.01
Female 27 (5.2) 1.00 1.00
Male 162 (8.7) 1.74 (1.14-2.65) 1.75 (1.14-2.69)
HIV transmission category risk 0.39
Non-IDU 13 (5.7) 1.00
IDU 111 (8.1) 1.46 (0.81-2.65)
Other/unknown 65 (8.4) 1.53 (0.83-2.83)
CDC clinical category 0.01 0.04
A/B 64 (6.3) 1.00 1.00
C 60 (10.3) 1.72 (1.19-2.48) 1.65 (1.12-2.41)
Unknown 65 (8.5) 1.39 (0.97-1.99) 1.30 (0.67-2.54)
Nadir CD41 T-cell count, cells/mm3 0.02
 200 38 (5.5) 1.00
< 200 85 (9.3) 1.74 (1.17-2.58)
Unknown 66 (8.6) 1.60 (1.06-2.42)
Baseline CD41 T-cell count, cells/mm3 <0.001 0.01
200 95 (6.7) 1.00 1.00
<200 21 (16.0) 2.64 (1.58-4.40) 2.30 (1.35-3.92)
Unknown 73 (8.8) 1.33 (0.97-1.83) 1.22 (0.65-2.30)
Baseline HIV RNA copies/mL 0.90
<50 122 (7.9) 1.00
50 6 (7.2) 0.91 (0.39-2.14)
Unknown 61 (8.3) 1.06 (0.77-1.46)
Combination ART 0.23
Yes 183 (7.9) 1.00
No 6 (12.8) 1.71 (0.72-4.08)
Liver stiffness, kPa* <0.001
<9.5 66 (6.6) 1.00
9.5-12.5 21 (5.2) 0.77 (0.46-1.27)
12.6-19.4 18 (4.7) 0.70 (0.41-1.19)
19.5 79 (14.4) 2.38 (1.68-3.36)
Unknown 5 (13.2) 2.13 (0.81-5.65)
HCV genotype 0.26
1 102 (7.1) 1.00
2 4 (14.8) 2.26 (0.77-6.67)
3 29 (8.2) 1.16 (0.75-1.78)
4 51 (9.6) 1.39 (0.97-1.97)
Other 3 (10.7) 1.56 (0.46-5.26)
HCV RNA IU/mL 0.047 0.01
<800,000 46 (6.3) 1.00 1.00
800,000 143 (8.7) 1.42 (1.01-2.00) 1.63 (1.14-2.36)
Naive for anti-HCV therapy 0.84
Yes 122 (8.1) 1.00
No 67 (7.8)
0
0.97 (0.71-1.32)
Liver disease category <0.001 <0.001
No cirrhosis 87 (6.2) 1.00 1.00†,‡
Compensated cirrhosis 72 (9.0) 1.50 (1.08-2.07) 1.35 (0.96-1.89)†,§
Decompensated cirrhosis 30 (19.2) 3.62 (2.30-5.70) 2.92 (1.76-4.87)‡,§
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treated with SOF/LDV plus RBV for 24 weeks, with
SVR rates of 89% and 90% by ITT and m-ITT analy-
ses; these results were substantially lower than the SVR
rates found with SOF1DCV with RBV for 24 weeks
(see above). SOF/LDV is not recommended for
patients infected with HCV genotype 3 because LDV
is less potent against genotype 3 than DCV or velpa-
tasvir.(3,4,27,28) In a trial with LDV/SOF plus RBV for
12 weeks in genotype 3 patients, the SVR rate was
100% in 26 treatment-naive patients, 6 of whom had
cirrhosis; however, in the 50 treatment-experienced
patients, the rates of SVR were 73% and 89% in those
with and without cirrhosis, respectively.(29) In a second
trial with 111 naive patients with HCV genotype 3
infections treated for 12 weeks with LDV/SOF plus
RBV, the SVR rates were 94% in 72 patients without
cirrhosis and 79% in 39 patients with compensated cir-
rhosis.(30) Taken together, the results of these trials
and the real-world experience of Madrid-CoRe sug-
gest that SOF/LDV should be considered a subopti-
mal regimen for genotype 3 infections in patients with
cirrhosis.
According to current guidelines, treatment of HCV
genotype 1 with LDV/SOF can be shortened to
8 weeks in treatment-naive patients without cirrhosis if
their baseline HCV RNA level is <6 million (6.8 log)
IU/mL.(3,4) This recommendation is based on the
observation that among ION-3 patients with baseline
HCV RNA <6 million IU/mL, relapse rates were
similar in those receiving 8 weeks of treatment and
those receiving 12 weeks of treatment.(31,32) In
Madrid-CoRe, 308 patients met the required condi-
tions for a short 8-week regimen of SOF/LDV with-
out RBV. Of these, 104 patients were treated for
8 weeks and 204 for 12 weeks with SVR rates by ITT
and m-ITT analyses of 92%-93% and 93%-95%,
respectively. The relapse rates were 5.8% and 3.9% in
the 8-week and 12-week arms, respectively. These
results are similar to those reported in the ION-3 trial,
in which 215 patients received SOF/LDV for 8 weeks,
with an SVR rate of 94% and a relapse rate of 5%.(32)
Real-world cohort data have also shown the compara-
ble effectiveness of SOF/LDV for 8 and 12 weeks in
HCV genotype 1–infected, treatment-naive patients
without cirrhosis.(21,33-36) Of note, the proportions of
patients with METAVIR F3 ﬁbrosis (or an equivalent
by transient elastography) treated with SOF/LDV for
8 weeks were 13% in the ION-3 trial and <25% in
Madrid-CoRe. Thus, the question remains as to
whether the 8-week LDV/SOF regimen is appropriate
for patients with METAVIR F3 in liver biopsy or
equivalent by noninvasive methods.
TABLE 5. Continued
Treatment
Failures (n 5 189) Univariable Multivariable
Variable n (%) OR (95% CI) P OR (95% CI) P
Anti-HCV regimen <0.001 <0.001
SOF/LDV 107 (7.3) 1.00 1.00
SOF1DCV 30 (8.7) 1.21 (0.79-1.84) 1.10 (0.71-1.70)
DSV1OBV/PTV/r 16 (5.1) 0.68 (0.40-1.17) 0.73 (0.42-1.27)
OBV/PTV/r 10 (7.6) 1.04 (0.53-2.04) 1.40 (0.70-2.79)
SOF1SMV 17 (23.9) 4.00 (2.24-7.14) 2.84 (1.53-5.29)
SOF1RBV 7 (21.9) 3.56 (1.50-8.42) 3.41 (1.39-8.36)
SMV1DCV 2 (50.0) 12.71 (1.77-91.1) 11.77 (1.59- 87.27)
SOF1SMV1DCV 0 — —
SOF1OBV/PTV/r 0 — —
Anti-HCV treatment duration 0.12
8 weeks 9 (6.9) 0.94 (0.47-1.90)
12 weeks 115 (7.3) 1.00
16 weeks 0 —
24 weeks 65 (9.8) 1.38 (1.01-1.90)
Ribavirin use 0.48
No 127 (7.7) 1.00
Yes 62 (8.6) 1.12 (0.82-1.54)
*Liver stiffness cutoffs: <9.5 kPa, cutoff accurate to rule out advanced ﬁbrosis-cirrhosis (METAVIR F3-F4); 12.5 kPa, cutoff accu-
rate to rule out liver cirrhosis; 19.5 kPa, cutoff accurate to rule out high-risk of esophageal varices.
†P 5 0.015.
‡P < 0.001.
§P < 0.001.
Abbreviations: CI, conﬁdence interval; OR, odds ratio; IDU, injection drug user.
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The high SVR rates of most currently licensed all oral
DAA-based regimens against HCV and the relatively
small number of patients included in registration trials
have made it difﬁcult to identify predictors of treatment
failure. Nevertheless, genotype 3, cirrhosis, liver decom-
pensation, and preexisting resistance-associated variants
all seem to reduce the probability of SVR.(11) The large
size of the Madrid-CoRe cohort permitted us to evaluate
predictors of treatment failure. Multivariable logistic
regression modeling showed that gender, infection-
related variables (HIV and HCV), severity of liver dis-
ease, and treatment-related variables were independently
associated with response to treatment.
Our multivariable model showed that the probability
of failure was highest for decompensated cirrhosis, inter-
mediate for compensated cirrhosis, and lowest for
absence of cirrhosis, with statistically signiﬁcant pair-wise
comparisons between the three groups. The importance
of the severity of liver disease in treatment outcomes is
further emphasized by our observation that among
patients with compensated cirrhosis the presence of a
liver stiffness value 19.5 kPa was associated with a sig-
niﬁcantly higher probability of treatment failure. This
cutoff deﬁnes a group of patients at risk of having
clinically signiﬁcant portal hypertension and esophageal
varices(12) and corresponds to the new category of com-
pensated advanced chronic liver disease in the report of
the Baveno VI Consensus Workshop.(37)
Male sex was a predictor of treatment failure in
Madrid-CoRe. Male sex, a recognized predictor of treat-
ment failure in the interferon plus RBV era,(38) has also
been associated with treatment failure in a large real-
world report of patients infected with HCV genotype 1
treated with SOF/LDV or DSV1OBV/PTV/r within
the US Veterans Affairs Health Care System.(33)
Of note, we found that CDC clinical category C and a
baseline CD41 T-cell count <200/mm3 were indepen-
dently associated with increased odds of treatment failure.
These ﬁndings suggest that the immune response may
play a role in clearance of HCV during DAA-based ther-
apies, possibly through the recognition and elimination by
T cells of viral variants with resistance to DAAs.(39) In a
German real-world cohort in the DAA era (395 HIV/
HCV-coinfected patients), the variables associated
with reduced odds of SVR were liver cirrhosis, a CD41
T-cell count <350/mm3, and a CD41 T-cell percentage
<20%; however, in the multivariable analysis, only liver
cirrhosis remained statistically signiﬁcantly associated
with treatment failure.(40) Sufﬁciently large cohorts of
HIV/HCV-coinfected patients and HCV-monoinfected
patients may reveal statistically signiﬁcant differences
(albeit not clinically relevant) in efﬁcacy rates between
both treatment groups after DAA therapy.
In Madrid-CoRe, HCV RNA load 800,000 IU/
mL was the only HCV-related factor independently
associated with treatment failure. To date, an associa-
tion between an HCV RNA load 800,000 IU/mL
and treatment failure has been reported in patients
with HCV genotype 1a treated with the combination
of elbasvir/grazoprevir.(41)
Finally, we found that the use of DAA regimens
including SOF1SMV, SOF1RBV, and SMV1DCV
was independently associated with treatment failure.
SOF1RBV and SMV1DCV are no longer included
in the recommended regimens for treating HCV in-
fection.(3,4) However, SOF1SMV is currently one of
the recommended regimens for genotype 1a or 1b in
treatment-naive and treatment-experienced, DAA-
naive patients without cirrhosis in the American Asso-
ciation for the Study of Liver Diseases–Infectious Dis-
eases Society of America guidelines(4) and for genotype
4 in treatment-naive and treatment-experienced,
DAA-naive patients without cirrhosis and patients
with compensated cirrhosis in the European Associa-
tion for the Study of the Liver guidelines.(3)
The main limitation of our study was that some base-
line HIV-related variables were collected retrospectively.
Moreover, this information was not available at the time
of the data analysis in approximately one third of patients,
who were attended in eight out of the 25 participating
hospitals and who did not send the information on time.
However, in our univariable and multivariable adjusted
models, patients for whom data were unavailable were
classiﬁed as “unknown.” Our study is also limited by the
lack of data on concomitant medication, including proton
pump inhibitors,(42) and adherence. Furthermore, the
absence of information on preexisting viral variants with
resistance-associated substitutions prevented us from ana-
lyzing their prevalence and their impact on treatment
outcomes.(43) Nevertheless, to our knowledge, Madrid-
CoRe is the largest real-world study of interferon-free
regimens in HIV/HCV-coinfected patients reported to
date, with two and a half times more patients than the
large series recently reported from the Veterans Adminis-
tration Health Care System (996 patients)(6) and almost
6 times more patients than all other reported series
(<400 patients).(7,8,10) This huge sample, which com-
pares favorably with the large real-world studies reported
for HCV-monoinfected patients,(11) gave us the opportu-
nity to assess treatment outcomes for various regimens
against different genotypes in different liver disease cate-
gories and to evaluate predictors of treatment response,
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which is difﬁcult to assess for a therapy with failure rates
<10%.
In conclusion, in this large real-world prospective
study, interferon-free DAA therapy was found to be
safe and highly effective in HIV/HCV-coinfected
patients. Our ﬁndings support the use of an 8-week reg-
imen of LDV/SOF without RBV for treatment-naive,
coinfected patients without cirrhosis with an HCV
RNA level <6 million IU/mL. They also support the
use of a 24-week regimen of SOF1DCV with RBV for
genotype 3 infection in coinfected patients with com-
pensated cirrhosis. The variables found to be indepen-
dently associated with treatment failure included
gender, CDC clinical category, baseline CD41 T-cell
count, HCV RNA load, cirrhosis, decompensated liver
disease, and the use of DAA regimens currently consid-
ered suboptimal in some guidelines.
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Appendix: The Madrid-CoRe
Study Group
1. Hospital General Universitario Gregorio
Mara~non: Berenguer J, Aldamiz T, Miralles T,
Lopez JC, Parras F, Gijon P, Padilla B, Montilla
P, Fernandez-Cruz A, Valerio M, Bermudez E,
Catalan P, Rodrıguez C
2. Hospital La Paz-Carlos III: Gonzalez JJ, Montes
ML, Martın L, Moreno V, Valencia E, Perez I,
Bernardino I, Jimenez I, Moreno F
3. Subdireccion General de Farmacia y Productos
Sanitarios/SERMAS: Gil A, Alcaraz M, Ara-
nguren A, Calvo MJ, Cruz E
4. Hospital Universitario Ramon y Cajal: Moreno
A, Quereda C, Casado J, Perez MJ, Vivancos
MJ, Diaz A, Navas E, Fortun J, Moreno S, Ser-
rano S, Garcıa M, Rodrıguez MA
5. Hospital Universitario Doce de Octubre: Pulido
F, Rubio R, Domınguez L, Matarranz M, de
Lagarde M, Fernandez I, Mu~noz R, Martın A,
Pinar O
6. Hospital Clınico Universitario San Carlos: Tellez
MJ, Estrada V, Vergas J, Cabello N, Saenz M,
Santiago A
7. Hospital Universitario de la Princesa: Santos I,
Martınez C
8. Hospital Universitario Prıncipe de Asturias: Sanz
J, De Miguel J, Arranz A, Casas E, Vıctor V,
Herrero M
9. Hospital Universitario Infanta Leonor: Ryan P,
Troya J, Cuevas G, Esteban C
10. Hospital Universitario Puerta de Hierro: Benıtez
L, Arias A, Dıaz A, Ba~nos I, Duca A, Menchen
B, Santiago M
11. Hospital Universitario de Getafe: Gaspar G,
Sanchez-Rubio J
12. Fundacion Hospital Jimenez Dıaz: Gorgolas A.
Alvarez B, Polo B, Varela A, Gonzalez A,
Cabello A, Calvo R, Porres JC, Bonilla M
13. Hospital Universitario Severo Ochoa: Torres R,
Cervero M, Jusadado JJ, Dıaz E
14. Hospital Universitario de Mostoles: Merino F,
Barros C, Corrales L
15. Hospital Fundacion de Alcorcon: Losa JE, Her-
vas R, Velasco M, Moreno L, Henrıquez C,
Perez M, Polanco M
16. Hospital de Fuenlabrada: San Martın J, Canalejo
E, Hinojosa J, Ruiz-Giardin JM, Aguilar C,
Hernandez B
17. Hospital de Torrejon: Arponen S, Gimeno A,
Montero MC
18. Hospital del Henares: Serrano R, Sanz P, Eg€ues
E, Tovar M
19. Hospital del Tajo: Monsalvo R, Terrancle I,
Pedraza LA
20. Hospital Infanta Elena: Vegas A, del Portillo A,
Collado V
21. Hospital Infanta Cristina: De Guzman MT,
Martınez JA, Perez JL, Melero JA, Matilla E
22. Hospital del Sureste: Garcıa MT, Pe~nalver R,
Capilla C, Fernandez-Amago MT
23. Hospital Rey Juan Carlos: Gotuzzo L, Marcos J,
Garcıa A
24. Hospital Infanta Sofıa: Malmierca E, Suarez I,
Portillo L
25. Hospital El Escorial: Belda L, Sanchez S
26. Hospital Gomez Ulla: Menendez MA
27. Instituto de Salud Carlos III: Jarrın I
28. Facultad de Farmacia, Universidad Complutense:
Benedi J
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